Optimize Lead Choice
Make decisions preclinically when comparing & combining cell therapies with new modalities1
Apply the power of polyfunctional strength to identify functional immune cell subsets which correlate with in vivo activity.
Identify differences and mechanism in combined cell therapies
PSI revealed differences in control and new combination therapy, enhancing decision making
NKTR-214 elicited more polyfunctional subsets than IL-2, which correlates with results from complementary technologies
Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2. Sorted antigen-specific CD8+ T cells Thy1.+ from tumors and spleen D7 after ACT+NKTR-214 or ACT+IL-2 (3 mice/group) were stimulated and stained with anti-mouse CD8.
NKTR2-14 elicited more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.